HNF is advancing and supporting clinical research and trials for CMT.
HNF has been instrumental in advancing and supporting clinical trials by providing valuable patient insight, innovative data collection, and regulatory initiatives to assist in industry-sponsored clinical trial design and to inform the FDA for decision-making and oversight during drug development and commercialization of drugs and gene therapies for CMT.
Learn about clinical trials and how you can participate.
Without your participation, researchers won’t have the essential patient information to develop drugs, gene therapies, and clinical trials for Charcot-Marie-Tooth and other Inherited Neuropathies. In addition, as GRIN grows, we gain greater insights from you as patients to help accelerate therapies for Charcot-Marie-Tooth (CMT) and Inherited Neuropathies.
CMT Thrive Webinar:
The Key Role CMT Patients Play in Research
Presented by: Joy Aldrich, HNF GRIN Patient Registry Coordinator
Learn more on this topic
Latest News and Related Blog Posts
Dr. Kayla Cornett to Present Groundbreaking CMT Wearable Sensor Study at MDA Clinical and Scientific Conference
On March 19th, at the MDA Clinical and Scientific Conference in Dallas, TX, Dr. Cornett will present exciting findings from the wearable sensor study conducted in collaboration with HNF’s partner, BioSensics. This innovative research highlights the potential of...
CMT Summit + Retreat 2025
CMT Summit + Retreat 2025: Uniting Patients, Researchers, Regulators, and Industry Leaders to Accelerate CMT Research Join patients, researchers, and industry leaders April 24-26 in Nashville to advance CMT research and empower wellness. The Hereditary Neuropathy...
Welcome to the CMT Simplified Podcast by the HNF
CMT Simplified is here to make staying informed about Charcot-Marie-Tooth disease (CMT) easier than ever! Each 10-20 minute episode delivers: Bite-sized updates on research breakthroughs Easy-to-understand insights into treatments Empowering knowledge—on the go!...
CMT Breakthrough: FDA Grants Orphan Drug Status to NMD670
NMD670, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA)
How Does CMT Affect You?
Join the thousands of HNF volunteers who are fueling CMT research. The more you share, the more we’ll learn. Complete your GRIN surveys today!
HNF Awards the inaugural HNF Clinical Translation Fellowship
HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla Cornett, PhD We are thrilled to announce the establishment of the HNF Clinical Translation Fellowship, awarded to Kayla Cornett, PhD, a distinguished postdoctoral research...
Breaking News for SORD Deficiency Patients
The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
HNF Contributes CMTRN Data to C-Path’s RDCA-DAP
HNF Contributes CMTRN Data to C-Path’s RDCA-DAP, Strengthening Research Capabilities for Inherited Neuropathies Integration of CMTRN data into RDCA-DAP promises new insights into Charcot-Marie-Tooth disease and related neuropathies, fueling advancements in treatment...
Breaking News: HNF to Host “Revolutionizing Clinical Trials” Panel at Bio 2024
HNF is thrilled to announce that we have been accepted to host a 1-hour panel discussion during the Bio International Convention in San Diego, CA, in June 2024.
CMT Biobank: We Need Your HELP!
HNF is excited to continue collecting samples for researchers and industry to help develop treatments for CMT.